Trial Profile
CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson's disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Trientine (Primary) ; Penicillamine
- Indications Hepatolenticular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms CHELATE STUDY
- Sponsors GMP-Orphan SAS; Orphalan
- 14 Nov 2023 Results assessing efficacy presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 14 Nov 2023 Results assessing the relationship between NCC-Sp and NCC-Ex and its development over time during chelator treatment, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 10 Nov 2022 This trial has been prematurely ended in Austria, according to European Clinical Trials Database record.